Jill Morrison, MD
Hematology-Oncology · Englewood, NJNPI 1184670952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Daiichi Sankyo Inc. at 24.9% of the total. 2025 is the largest year on record at $1,583, more than ten times the $145 reported in 2019.
Across 180 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$900
- Gilead$555
- AstraZeneca$442
- Johnson & Johnson$305
- Novartis$196
- Pfizer$172
- plus $1K from 25 others
Across 48 payments — averaging $84,423 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.9M
- Aadi Bioscience, Inc.$93K
- Pfizer$43K
- E.r. Squibb & Sons, L.L.C.$7K
- Bristol Myers Squibb$1K
What the payments were for
- Food & beverage$3,45996%
- Education$1544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 51 | $900 |
| Gilead | 29 | $555 |
| AstraZeneca(2 entities) | 20 | $442 |
| Johnson & Johnson(3 entities) | 7 | $305 |
| Novartis | 9 | $196 |
| Pfizer | 10 | $172 |
| Merck | 8 | $123 |
| Tempus AI, Inc | 4 | $107 |
| Incyte Corporation | 3 | $106 |
| Bayer | 3 | $70 |
| Lilly USA, LLC | 4 | $69 |
| Bristol Myers Squibb | 4 | $60 |
| GSK | 3 | $50 |
| Myriad Genetic Laboratories, Inc. | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Genentech USA, Inc. | 2 | $43 |
| Sanofi | 2 | $41 |
| Stemline Therapeutics Inc. | 2 | $33 |
| AbbVie | 2 | $31 |
| Novocure Inc. | 1 | $28 |
| Exelixis Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Geron Corporation | 1 | $17 |
| Aadi Bioscience, Inc. | 1 | $17 |
| Veloxis Pharmaceuticals, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Curium US LLC | 1 | $13 |
| ADC Therapeutics America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUMATCH$154
How this compares
Too few hematology-oncology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrserduElacestrant Hcl | 14 | $321,099 |
| KisqaliRibociclib Succinate | 20 | $296,843 |
| Everolimus | 21 | $30,246 |
| XareltoRivaroxaban | 17 | $17,762 |
| Exemestane | 97 | $16,736 |
| EliquisApixaban | 23 | $16,327 |
| Anastrozole | 518 | $10,663 |
| Tamoxifen Citrate | 106 | $3,833 |
| Raloxifene Hcl | 33 | $1,796 |
| Letrozole | 32 | $638 |
| Estradiol | 12 | $374 |
| Alendronate Sodium | 35 | $285 |
| Dexamethasone | 16 | $208 |
| Pantoprazole Sodium | 16 | $140 |
| Ondansetron Hcl | 13 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Stemline Therapeutics Inc.Orserdu | $33 | $321,09914 claims |
| NovartisKisqali | $196 | $296,84320 claims |
| Johnson & JohnsonXarelto | $305 | $17,76217 claims |
| PfizerEliquis | $172 | $16,32723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Englewood
- Lewis AttasEnglewood$6K
- Trina PorettaVoorhees$91K
- Richard GordonVoorhees$41K
- Kush SachdevaVineland$15K
- Richard ScherLittle Silver$7K
- Asmita AhujaMontclair$3K
- Beata PieczaraTeaneck$2K
- Yadyra RiveraTeaneck$1K
- Ian HorkheimerLittle Silver$1K
- Raimonda GoldmanTeaneck$810
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.